12:51 AM EDT, 10/26/2026 (MT Newswires) -- Genmab (GMAB.CO) reported "encouraging" objective response rates following follow-up analyses of a mid-stage study evaluating petosemtamab plus Folfox or Folfiri as a treatment for patients with metastatic colorectal cancer, or mCRC. The Danish biotechnology company said Sunday that a confirmed objective response rate of 75% and an unconfirmed objective response rate of 67% were observed at a median follow-up of 5.9 months and 7.1 months in first- and second-line treatment settings, respectively. The combination therapy is currently being assessed in a global phase 3 development program in mCRC. The updated results were presented at the European Society for Medical Oncology Congress 2026 in Madrid.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.